J Appl Biomed 11:71-78, 2013 | DOI: 10.2478/v10136-012-0024-9
Circadian variation in haematological toxicity of the immunosuppressive agent "Mycophenolate Mofetil" in rats
- 1 Laboratory of Pharmacology, Faculty of Medecine, University of Monastir, Tunisia
- 2 Laboratory of Hematology, CHU Fattouma Bourguiba, Monastir, Tunisia
- 3 Laboratory of Biomonitoring of the Environment (LR01/ES14), Faculty of Science of Bizerta, University of Carthage, Bizerta, Tunisia
- 4 Unit of Chronobiology, Foundation A. de Rothschild Paris, France
Because of biological rhythms, drug efficiency and toxicity vary according to the time of administration of the drug. This study investigates whether the haematological toxicity of the immunosuppressive agent Mycophenolate Mofetil varies according to the circadian dosing-time in rats. 300 mg/kg of Mycophenolate Mofetil was injected by i.p. route to different groups of animals at six different circadian stages (1, 7, 13, and 19 hours after light onset, i.e., HALO). Mycophenolate Mofetil treatment induced a significant decrease at 7 HALO in red blood cells (-18%), in haemoglobin rate (-15%) and in white blood cells (-54%). These parameters followed a circadian rhythm with an acrophase located at the end of the light-rest phase. A significant thrombocytopenia was observed according to Mycophenolate Mofetil the circadian dosing-time. In the controls, the number of platelets followed a circadian rhythm. Mycophenolate Mofetil modified this rhythm which became an 8-h ultradian rhythm. The data indicate that, the Mycophenolate Mofetil-induced haematological toxicity was maximum when the drug was administered in the middle of the light-rest phase, which is physiologically analogous to the end of the activity of the diurnal phase in human patients.
Keywords: circadian rhythm; immunosuppressive agent; MMF; hematological toxicity; rat
Received: September 12, 2012; Revised: November 6, 2012; Published: July 31, 2013 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Ben-Cherif W, Dridi I, Aouam K, Ben-Attia M, Reinberg A. Chronotolerance study of the antiepileptic drug valproic acid in mice. J Circadian Rhythms. 10: 3, 2012.
Go to original source...
Go to PubMed...
- Berger J. The age of biomedicine: current trends in traditional subjects. J Appl Biomed. 9: 57-61, 2011.
Go to original source...
- Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 34: 429-455, 1998.
Go to original source...
Go to PubMed...
- Cantarovich M, Brown NW, Ensom MH, Jain A, Kuypers DR, Van Gelder T, Tredger JM. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplant Rev. 25: 65-77, 2011.
Go to original source...
Go to PubMed...
- Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. 36: 703-704, 2004.
Go to original source...
Go to PubMed...
- Danesi R, Mosca M, Boggi U, Mosca F, Del Tacca M. Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today. 6: 475-482, 2000.
Go to original source...
Go to PubMed...
- Dridi I, Ben-Cherif W, Aouam K, Ben-Attia M, Reinberg A, Boughattas NA. Murine circadian time-dependent tolerance to the immunosuppressive agent mycophenolate mofetil (MMF). Biol Rhythm Res. 1-9, 2012.
Go to original source...
- EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.1. Anaemia. Nephrol Dial Transplant. 17: 48, 2002a.
- EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Leukopenia. Nephrol Dial Transplant. 17: 49, 2002b.
- Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci. 685: 309-329, 1993.
Go to original source...
Go to PubMed...
- Halberg F. Chronobiology. Annu Rev Physiol. 31. 675-725, 1969.
Go to original source...
Go to PubMed...
- Haus E. Biologic rhythms in hematology. Pathol Biol. 44: 618-630, 1996.
- Haus E, Smolensky MH. Biologic rhythms in the immune system. Chronobiol Int. 16: 581-622, 1999.
Go to original source...
Go to PubMed...
- Haus E, Lakatua DJ, Swoyer J, Sackett-Lundeen L. Chronobiology in hematology and immunology. Am J Anat. 168: 467-517, 1983.
Go to original source...
Go to PubMed...
- Khedhaier A, Ben-Attia M, Gadacha W, Sani M, Bouzouita K, Chouchane L, Mechkouri M, Reinberg A, Boughattas NA. Circadian Rhythms in Toxic Effects of the Serotonin Antagonist Ondansetron in Mice. Chronobiol Int. 20: 1103-1116, 2003.
Go to original source...
Go to PubMed...
- Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 12: R208, 2010.
Go to original source...
Go to PubMed...
- Mackie F, Verran D, Horvath J, Tiller D. Severe thrombocytopenia with OKT3 use for steroid-resistant rejection in a cadaveric renal transplant recipient. Nephrol Dial Transplant. 11: 2378, 1996.
Go to original source...
Go to PubMed...
- Nelson W, Tong YL, Lee JK, Halberg F. Methods for cosinor-rhythmometry. Chronobiologia. 6: 305-323, 1979.
Go to PubMed...
- Neumann I, Haidinger M, Jäger H, Grützmacher H, Griesmacher A, Müller MM, Bayer PM, Meisl FT. Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients. J Am Soc Nephrol. 14: 721-727, 2003.
Go to original source...
Go to PubMed...
- Ohkura K, Uto Y, Nagasawa H, Hori H. Effect of molecular chirality and side chain bulkiness on angiogenesis of haloacetylcarbamoyl-2-nitroimidazole compounds. Anticancer Res. 27: 3693-3700, 2007a.
- Ohkura N, Oishi K, Sekine Y, Atsumi G, Ishida N, Matsuda J, Horie S. Comparative Study of Circadian Variation in Numbers of Peripheral Blood Cells among Mouse Strains: Unique Feature of C3H/HeN Mice. Biol Pharm Bull. 30: 1177-1180, 2007b.
Go to original source...
Go to PubMed...
- Ottaway CA, Husband AJ. The influence of neuroendocrine pathways on lymphocyte migration. Immunol Today. 15: 511-517, 1994.
Go to original source...
Go to PubMed...
- Pally C, Tanner M, Rizvi H, Papageorgiou C, Schuurman HJ. Tolerability profile of sodium mycophenolate (ERL080) and mycophenolate mofetil with and without cyclosporine (Neoral) in the rat. Toxicology. 157: 207-215, 2001.
Go to original source...
Go to PubMed...
- Piccione G, Fazio F, Giudice E, Grasso F, Morgante M. Nycthemeral change of some haematological parameters in horses. J Appl Biomed. 3: 123-128, 2005.
Go to original source...
- Reinberg AE. Concepts in chronopharmacology. Annu Rev Pharmacol Toxicol. 32: 51-66, 1992.
Go to original source...
Go to PubMed...
- Sani M, Sebai H, Boughattas NA, Ben-Attia M. Time-of-day dependence of neurological deficits induced by sodium nitroprusside in young mice. J Circadian Rhythms. 9: 5, 2011.
Go to original source...
Go to PubMed...
- Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. The US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60: 225-232, 1995.
Go to original source...
Go to PubMed...
- Tsutsumi H, Monnai Y, Ishii H, Tanioka Y, Tanigawa M. Diurnal variation and effects of fasting on blood constituent in minipigs. Exp Anim. 48: 247-254, 1999.
Go to original source...
Go to PubMed...
- Virji M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant. 5: 293-296, 2001.
Go to original source...
Go to PubMed...
- Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, Oellerich M, Tönhoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 13: 759, 2002.
Go to original source...
Go to PubMed...